Comparison of two marketed effervescent fast relief formulations for antacid activity—an in vitro study

Pranjali P. Dhawal1*, Siddhivinayak S. Barve1, Dyotona Sen-Roy2

1Department of Animal Biotechnology and Biochemistry Division, Kelkar education trust's Scientific Research Centre, Mumbai, Maharashtra, India
2Abbott India Limited, Floor 16, Godrej BKC, Mumbai, Maharashtra, India

Received: 23 March 2021
Revised: 28 April 2021
Accepted: 29 April 2021

*Correspondence:
Pranjali P. Dhawal,
Email: animalbiotechnologysrc@gmail.com

ABSTRACT

Background: Hyper-acidity is excessive formation of acid (pH=1.5-3.5) in the stomach by parietal cells which causes a burning sensation in the chest. The preservation of gastric acid insult is crucial because of the implications of hyperacidity in gastroesophageal reflux disease (GERD), peptic ulcers and duodenal ulcers. Acidity is controlled by use of some over-the-counter (OTC) antacid formulations containing magnesium or aluminum hydroxides.

Methods: In the present study, the preliminary antacid test (PAT), the pH acid neutralizing capacity (ANC), acid neutralizing potential (ANP) along with buffering capacity of two well-known quick release formulations (F1 [Digene Ultra Fizz] and F2 [a standard, commercially available product]) were determined.

Results: According to US pharmacopeia USP, both the antacid formulations passed the PAT test. PAT results revealed that the pH of the acid-antacid solution was higher in F1 (8.20±0.02) as compared to F2, (6.53±0.01). The ANC results revealed that F1 (46.89±0.6 mEq/dosage) had higher neutralizing capacity as compared to F2(30.12±1.3 mEq/dosage). Higher ANP was observed for F1 (245 mins), and it was 2.7 times that of F2 (90 min). The onset of action for both the antacids was <2 seconds. Additionally, buffering capacity was evidently observed during ANP analysis in the case of F1. Independent T test performed for all the tests revealed that the data obtained was highly significant (p<0.01).

Conclusions: F1 showed high antacid and buffering properties when tested in vitro. The present study highlights the need for future research on specific OTC non-prescribed antacid formulations with respect to their price, efficacy and side effects.

Keywords: Acid neutralizing capacity, Acid neutralizing potential, Preliminary antacid test

INTRODUCTION

Excessive formation of acid in the stomach by parietal cells causes a burning sensation in the chest, along with reflux termed hyperacidity. Commonly available treatment includes gastric acid blockers, proton pump inhibitors, tissue lining protection drugs, over-the-counter antacids and antibiotics for hyperacidity due to Helicobacter pylori.1,2 Antacids are weak bases (hydroxide, citrate, carbonate, bicarbonate) combined with metallic ions (aluminum, calcium), classified as systemic or non-systemic, and are capable of neutralizing gastric acidity.3 Variables that affect a patient’s imbalance between acid secreting mechanism of stomach and protective mechanisms of the gastric mucosa are faulty eating habits, smoking, tobacco chewing, stress, improper sleep, and anxiety.4,5

The easy and inevitable use of antacids and treatment regimens suggests their long-term use. This can inadvertently affect the gastric mucosa causing alkalosis.
and retention of fluid. A study conducted by Rana et al suggested that prolonged use of an effervescent antacid shows no side effect till 30 days.4

This study is an extended research to our previously published work on different antacid formulations.6 In this paper, we aimed to determine the pH of F1 to frequently used antacid powder F2 and to study the antacid properties of both the marketed formulations. The need for evaluating different antacid formulations rely on the fact that medical institutions should be aware of composition, efficacy, dosage and side effects of different antacid formulations. Digene Ultra Fizz (F1), a product of Abbott India, is a combination of Svarjiksara (sodium bicarbonate), Nimbukamlam (citric acid) and Khatikachurna (calcium carbonate). F1, an over-the-counter OTC non-prescription drug, provides symptomatic relief from heartburn, acid indigestion, and sour stomach. F2, a marketed product is a combination of Svarjiksar (Shudh) and Nimbukamlam (Shushkam). Common antacid formulations contain tartaric acid, citric acid, sodium-bi-carbonate and sodium carbonate.7

Citric acid (Nimbukamlam) is essentially added to the antacid formulation to aid gas removal, flatulence relief, and relief from abdominal discomfort. Baking soda and citric acid together has potential to control and neutralize acidity.6 Sodium bicarbonate (Svarjiksara) used in antacid formulations reacts with acid and forms NACL, H2O, and CO2. Sodium chloride is the effect of neutralized acid and CO2 relieves abdominal discomfort.5 Calcium carbonate (Khatikachurna) is a potent, rapid and inexpensive acid neutralizer and has been known to prevent constipation.9

Liquid gels or quick release antacid formulations are more effective as compared to antacids in tablet form available in the Indian pharmaceutical market to ensure instant relief from heart burn and acidity. Various brands of OTC antacids are available in the market, with reports suggesting disparity in performance amongst these formulations. Acid neutralizing capacity and buffering capacity of any antacid explains the efficiency of the antacid performance in vivo. New formulations are created to tackle the pre-existing side effects of any antacid available in market and to meet new demands in terms of symptomatic and quick relief. In the current study, a marketed antacid fizz formulation, F2 was used as a standard to compare the preliminary antacid test, acid neutralizing capacity and acid neutralizing potential of F1, Digene Ultra Fizz, an antacid product of Abbot India limited.

METHODS

In the current study, in vitro tests were conducted to compare the antacid properties of Digene Ultra Fizz (F1) with those of the reference standard F2. The experiments were conducted in the Department of Animal Biotechnology and biochemistry and department of chemistry (FDA approved) in Kelkar Education Trust's
10 ml of 0.5M HCl was added to the solution of antacid prepared above while stirring on a magnetic stirrer at 300±30 RPM for 10 minutes. After 10 min, the pH was recorded using a pH meter calibrated at pH 1.0, 4.0 and 7.0. The pH of the solution was noted, and the samples were processed for ANC and ANP if the PAT showed a result of pH above 3.5 (food and drug administration, HHS, part 331).6

**Acid neutralizing capacity**

Various invitro tests are available to evaluate the performance of antacids such as acid neutralizing capacity (ANC), pH stat, among others.15 ANC is a measure to determine ability of an antacid to neutralize acid and is expressed as number of milli-equivalents of HCl that can be neutralized by one standard dose of antacid preparation.16

For estimating ANC of samples, one packet each of the products was added in a 100 ml conical flask containing 10 ml of distilled water and the solution was stirred at 300±30 RPM till the reaction subsided. The volume was then made up to 70 ml with distilled water while stirring at 300±30 RPM on a magnetic stirrer. The stirring was followed for another one minute.

To study the ANC of the antacid formulations, 60 ml of 1.0 HCl was added to the 70 ml antacid-water solution. The stirring was continued for another 10 min at 300±30 RPM on a magnetic stirrer. The unutilized HCl from the flask was back titrated using 0.5 N NaOH standardized with KHPh-potassium hydrogen phthalate. Titration was completed within 5 min and the endpoint was noted when the pH of 3.5 and below was obtained. The ANC was stated as mEq of acid neutralized by the given antacid solution.

Total mEq of antacid sample=(60.0 ml) (Normality of HCl)-(ml of NaOH required for neutralization) (Normality of NaOH).

The experiments were conducted in triplicates. Upon using KHPh for determining the normality of NaOH and HCl, the values were substituted in the formula and ANC was calculated.6,17

**Acid neutralizing potential**

Rosett Rice Test is an acid neutralizing dynamic test. The procedure attempts to simulate gastric conditions and record pH profile towards acid neutralization of the antacid under test.18

In order to determine the ANP of antacid effervescent formulations, one packet each of the products was added in a 100 ml conical flask containing 10 ml of distilled water and the solution was stirred at 300±30 RPM till the reaction subsided. The volume was then made up to 30 ml with distilled water while stirring at 300±30 RPM on a magnetic stirrer. The stirring was followed for another one minute.

The acid reactivity of the antacids was determined using Rossett-Rice procedure. To the water-antacid solution, 70 ml of 0.1 N HCl was added and the contents were stirred for 10 min at 300±30 RPM on a magnetic stirrer. The pH meter and a pump calibrated to deliver a constant volume 2.0 ml of 0.1 N HCl per min were activated. The pH time profile was recorded throughout the test until the pH of the solution fell below 3.0 and it was constant for a minute.6

**Onset of action**

For the onset of action, one packet of each product was added in a 100 ml conical flask containing 10 ml of distilled water and the solution was stirred at 300±30 RPM till the reaction subsided. The volume was then made up to 30 ml with distilled water while stirring at 300±30 RPM on a magnetic stirrer. The stirring was followed for another one minute.

The prepared solution of 0.1 N HCl was kept on a magnetic stirrer at 300±30 RPM with a pH electrode dipped in the flask. The sample solution was added to the flask containing 0.1 N HCl and time taken for pH to rise above 3.5 was recorded.6

**Statistical analysis**

For the obtained data two samples independent t test analysis was conducted using PAWS statistics 18.

**RESULTS**

**Standardization of NaOH and HCl**

The average volume of NaOH required to neutralize 0.26 g of KHPh was 2.2 ml. Upon substituting in the formula, the calculated normality of NaOH was found to be 0.559 N. This 0.559 N NaOH was used to neutralize 10 ml of 1.0 N HCl and the average volume of NaOH required was 18.3 ml. The calculated normality was 1.022 N(calculated) for HCl.

**Preliminary antacid test**

The preliminary antacid test (PAT) results are given as average±standard deviation in Table 1. Both formulations can be classified as antacids as their pH is >3.5.

**Table 1: PAT results of the marketed effervescent formulations.**

<table>
<thead>
<tr>
<th>Sample</th>
<th>Average</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Digene ultra fizz F1</td>
<td>8.20*</td>
<td>0.026458</td>
</tr>
<tr>
<td>F2</td>
<td>6.53*</td>
<td>0.017321</td>
</tr>
</tbody>
</table>

*Indicates the difference in the mean is statistically significant (p<0.001)
Acid neutralizing capacity

The volume of NaOH is added to the antacid-HCl solution to determine unutilized or un-neutralized HCl. More the amount of NaOH required, lesser is the ANC of the given antacid under given experimental conditions. Table 2 gives the ANC of F1 and F2.

From the results, it is evident that F1 showed higher ANC as compared to F2.

<table>
<thead>
<tr>
<th>Sample</th>
<th>ANC</th>
<th>Average</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Digene ultra fizz F1</td>
<td>46.944</td>
<td>46.211</td>
<td>0.667122</td>
</tr>
<tr>
<td>F2</td>
<td>29.65</td>
<td>30.123</td>
<td>1.386048</td>
</tr>
</tbody>
</table>

*Indicates the difference in the mean is statistically significant (p=0.008)

Table 2: ANC results of the marketed effervescent formulations.

Acid neutralizing potential and onset of action

Both the samples could raise pH above 3.5 for more than 90 min. F1 raised the pH above 3.5 and maintained it there with constant acid influx for 245 minutes. While conducting the experiment it was evident that with even 2 ml of 0.1 N HCl added per min to the antacid solution, F1 could raise the pH, however, with F2 there was an alteration in pH once it was lowered. This shows that F1 could demonstrate buffering capacity, while F2 could simply raise the pH of the solution. Table 3 represents the ANP and onset of the action of F1 and F2.

Table 3: ANP results of the marketed effervescent formulations.

<table>
<thead>
<tr>
<th>Sample</th>
<th>Initial pH</th>
<th>Time Taken to reach (in mins)</th>
<th>Max pH</th>
<th>To maintain pH above 3.5</th>
<th>Final pH</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Onset of action</td>
<td>Above pH 3.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Digene ultra fizz F1</td>
<td>&lt;2 seconds</td>
<td>&lt;2 seconds</td>
<td>1 min</td>
<td>245 min*</td>
<td>2.74</td>
</tr>
<tr>
<td>F2</td>
<td>&lt;2 seconds</td>
<td>&lt;2 seconds</td>
<td>2 min</td>
<td>90 min*</td>
<td>2.82</td>
</tr>
</tbody>
</table>

*Indicates the difference in the mean is statistically significant (p=0.001), N=3

DISCUSSION

There is a need to study marketed antacid formulations on a regular basis to determine their dosage, efficacy, safety along with economic considerations. The market is flooded with antacids and physicians are baffled with the existing choices available in market. The decision to choose proper antacid must be done on the basis of high ANC and the ability to maintain pH above 3.5 for a longer period with buffering capacity. This buffering capacity shall reduce the changes of acid rebound. Thus, hospital settings should have information of antacids with regards to their ANC, ANP and BC for proper patient care and management of gastric acidity associated disorders. F2, a well-established non-prescription-based OTC drug, was used as a standard while determining the PAT, ANC, and ANP of Digene Ultra Fizz. According to food and drug administration, HHS, part 331. Antacid products for over-the-counter (OTC) human use, if the PAT values are less than 3.5, the antacid under study shall not be labeled as an antacid. Also, if pH is greater than 3.5, only then ANC can be determined. The PAT values of both F1 and F2 were greater than 3.5. The ANC of Digene Ultra fizz was 1.53 times more than F2. Similarly, a higher ANP was noted with Digene Ultra Fizz F1 also, Digene Ultra Fizz (F1) showed buffering capacity in comparison to F2, a marketed formulation. In the case of F2, it was noted that the pH rose initially when HCl was added due to the ANC of F2 formulation. However, with the subsequent addition of HCl to examine the effect of acid-reflux, the pH only decreased by unit proportional to amount of HCl added without any buffering effect. However, with Digene Ultra Fizz F1, it was noted that the pH decreased with the addition of HCl and was subsequently increasing due to the antacid to rise above the existing decrease in pH by a few units. This explains the buffering capacity of F1 and this may be the reason that F1 could maintain pH above 3.5 for longer time duration of 245 mins as compared to 90 minutes with F2. Buffering capacity along with high ANC indicates higher efficiency of F1 as compared to F2.

Limitations

The study findings are limited by the fact that antacid effectiveness may alter due to many parameters such as interaction of with other drugs, food or gastric emptying. Since this study focuses on determination of in vitro antacid effectiveness, further research is warranted to study their efficiencies on actual human volunteers.

CONCLUSION

Considering the widespread use of antacids, antacids are proven to be safe and effective agents. However, it is important for the better understanding of the consumers that the products display efficacy and buffering capacity of the antacid. This helps explain medical rationale, efficacy and cost comparison between antacid products. Digene Ultra Fizz F1 was found to exhibit higher PAT, ANC, buffering capacity and ANP than the antacid formulation.
F2 when tested in vitro. Both Ultra Fizz and F2 can be used by patients with hyperacidity owing to the fact that both products showed high ANC. However, more data from clinical studies is required to better understand dosage, efficacy, and safety profile of both the products in human volunteers.

ACKNOWLEDGEMENTS

The author would like to thanks to Abbott India Ltd, India for funding the project. The samples tested for in vitro antacid properties were obtained from Abbott India Ltd.

Funding: Funding sources by Abbott India Ltd
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES
